Glenmark Pharmaceuticals
As of the edition of 20 October 2026, Glenmark Pharmaceuticals runs 4 drugs; it is on route A at 5 targets and on route B at 0 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
Drugs by status
| Status | Count |
|---|---|
| Went quiet | 4 |
| Total | 4 |
Where it needs a new molecule
Route A at 5 targets, route B at 0 targets.
All 5 rows on route A or B
In the product5 company-target rows on route A or B; 2 are not shown here, and no score is.
See all 5 targets where Glenmark Pharmaceuticals needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Immune system: 2 trials led
- Bones, joints and muscles: 1 trials led
- Hormones: 1 trials led